# Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

> **NCT00414869** · PHASE2 · TERMINATED · sponsor: **Forest Laboratories** · enrollment: 11 (actual)

## Conditions studied

- Portal Hypertension

## Interventions

- **DRUG:** NCX-1000
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00414869
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Preliminary analysis of 11 patients did not demonstrate the efficacy required.
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414869, "Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00414869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*